Suppr超能文献

全外显子测序在鉴别原发性和继发性肺癌中的作用

The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers.

作者信息

Vokes Natalie I, Zhang Jianjun

机构信息

Department of Thoracic and Head and Neck Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Lung Cancer (Auckl). 2021 Dec 2;12:139-149. doi: 10.2147/LCTT.S272518. eCollection 2021.

Abstract

Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often require adjuvant chemotherapy or may in fact be incurable stage IV lesions. Conversely, MLTs that represent distinct primaries have a better prognosis and may be overtreated if inappropriately classified as related secondaries. Historically, pathologic and radiographic criteria were used to distinguish between primary and secondary MLTs; however, the advent of genomic profiling has demonstrated limitations to these historic classification systems. In this review, we discuss the use of molecular profiling to distinguish between primary and secondary lung cancers, with a focus on the insights gleaned from whole exome sequencing (WES) analyses. While WES is not yet feasible in routine clinical practice, WES studies have helped elucidate the clonal relationship between primary and secondary lung cancers and provide important context for the application of targeted sequencing panel-based analyses.

摘要

出现多发性肺肿瘤(MLTs)的非小细胞肺癌(NSCLC)对准确分期和预后提出了挑战。作为来自共同原发灶的克隆相关继发性转移灶出现的MLTs分期较高,通常需要辅助化疗,或者实际上可能是无法治愈的IV期病变。相反,代表不同原发灶的MLTs预后较好,如果被不恰当地归类为相关继发性肿瘤,可能会受到过度治疗。从历史上看,病理和影像学标准被用于区分原发性和继发性MLTs;然而,基因组分析的出现已证明这些历史分类系统存在局限性。在本综述中,我们讨论了使用分子分析来区分原发性和继发性肺癌,重点是从全外显子测序(WES)分析中获得的见解。虽然WES在常规临床实践中尚不可行,但WES研究有助于阐明原发性和继发性肺癌之间的克隆关系,并为基于靶向测序panel的分析应用提供重要背景。

相似文献

引用本文的文献

1
Diagnosis and management of multiple primary lung cancer.多原发性肺癌的诊断与管理
Front Oncol. 2024 Oct 1;14:1392969. doi: 10.3389/fonc.2024.1392969. eCollection 2024.

本文引用的文献

4
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
7
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验